Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial
Pain Medicine · 01.11.2026 · 27 (11) · 1200-1209
DOI: 10.1093/pm/pnag093 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, online erschienen am 03.08.2026. Verfasst von Subrata Pahari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, Nil Ratan Sircar Medical College & Hospital, Kolkata, India. Hauptthemen laut MEDLINE: Lidocaine, Low Back Pain, Anesthetics, Local, Chronic Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Importance Evidence supporting repeated intravenous lidocaine infusions for probable nociplastic chronic non-specific low back pain remains limited despite its use as a centrally acting analgesic in several chronic pain conditions.
Objective
To evaluate whether repeated intravenous lidocaine infusions provide clinically meaningful benefit beyond placebo for pain reduction in probable nociplastic chronic non-specific low back pain.
Setting
Department of Physical Medicine and Rehabilitation, NRS Medical College and Hospital.
Participants
Eighty-four adults with chronic non-specific low back pain and probable nociplastic pain features.
Interventions
Participants were randomized equally to receive either intravenous lidocaine (1 mg/kg bolus followed by 4 mg/kg infusion weekly for 4 weeks) or placebo saline infusion. All participants received background multimodal pain management consisting of amitriptyline and aerobic exercise. Main Outcomes The primary endpoint was the between-group difference in Visual Analogue Scale (VAS) pain intensity at 3 months. Therapeutic equivalence was assessed using a prespecified equivalence margin of ±1.5 VAS units and the two one-sided tests (TOST) framework. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index [PSQI]) and functional disability (Quebec Back Pain Disability Scale [QBPDS]).
Results
At 3 months, the between-group difference in VAS was 0.24 (90% CI, −0.33 to 0.81), entirely within the predefined equivalence bounds, confirming therapeutic equivalence (TOST P < .001). Both groups improved significantly over time without a significant group × time interaction. Improvement in sleep quality was greater in the lidocaine group (mean difference in change score, 1.81; 95% CI, 0.49-3.14; P = .027). Functional improvement numerically favored lidocaine, although continuous disability outcomes were not significantly different. Adverse events were more common in the lidocaine group but were mild, transient, and self-limiting.
Conclusion
Repeated intravenous lidocaine infusions did not provide additional analgesic benefit over saline infusions administered alongside multimodal pain management in patients with probable nociplastic chronic non-specific low back pain. Relevance These findings support prioritizing evidence-based multimodal pain management, including exercise and centrally acting pharmacological therapy, over routine adjunctive intravenous lidocaine for probable nociplastic chronic non-specific low back pain. Clinical trial registration number CTRI/2024/07/070888. Clinical trials Registry-India (CTRI) https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTA4ODk1&Enc=&userName=.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physical Medicine and Rehabilitation, Nil Ratan Sircar Medical College & Hospital, Kolkata, India.
ORCID-Profile: Subrata Pahari, Sandipan Hazra, Partha Pratim Das
Zitieren
APA
Pahari, S., Hazra, S., & Das, P. P. (2026). Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial. Pain Medicine, 27(11), 1200-1209. https://doi.org/10.1093/pm/pnag093
Vancouver
Pahari S, Hazra S, Das PP. Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial. Pain Medicine. 2026;27(11):1200-1209. doi:10.1093/pm/pnag093
BibTeX
@article{Pahari2026,
author = {Pahari, Subrata and Hazra, Sandipan and Das, Partha Pratim},
title = {Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial},
journal = {Pain Medicine},
year = {2026},
volume = {27},
number = {11},
pages = {1200--1209},
doi = {10.1093/pm/pnag093}
}
EUVIMED